Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
CT CTMX CytomX Therapeutics, Inc. FY ended Dec 31, 2025 | $3.21 | $699.46M | $423.24M | $76.20M | -$14.10M | -$17.37M | -2.77x | 9.18x | — |
ID IDYA IDEAYA Biosciences, Inc. FY ended Feb 13, 2026 | $40.11 | $3.87B | $3.30B | $218.71M | -$113.67M | -$113.70M | -31.34x | 17.70x | — |
OC OCGN Ocugen, Inc. FY ended Feb 24, 2026 | $1.32 | $447.63M | $474.45M | $4.41M | -$65.42M | -$67.85M | -5.08x | 101.43x | — |
CL CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE FY ended Dec 31, 2025 | $4.23 | $2.22B | $2.09B | $1.92B | -$85.24M | -$85.55M | -9.61x | 1.15x | — |
CT CTXR Citius Pharmaceuticals, Inc. FY ended Dec 17, 2025 | $0.60 | $16.53M | $38.75M | $90.00K | -$38.67M | -$39.74M | -0.18x | 183.66x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | — | 0/5 | — | — | No saved peers have usable coverage for this method. |
Price / Sales PSActive | Equity Multiple | 62.62x | 5/5 | $3.69M | $0.07 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -9.79x | 5/5 | $766.50M | $14.29 | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
CT CTMX CytomX Therapeutics, Inc. FY ended Dec 31, 2025 | $3.21 | $699.46M | $423.24M | $76.20M | -$14.10M | -$17.37M | -2.77x | 9.18x | — |
ID IDYA IDEAYA Biosciences, Inc. FY ended Feb 13, 2026 | $40.11 | $3.87B | $3.30B | $218.71M | -$113.67M | -$113.70M | -31.34x | 17.70x | — |
OC OCGN Ocugen, Inc. FY ended Feb 24, 2026 | $1.32 | $447.63M | $474.45M | $4.41M | -$65.42M | -$67.85M | -5.08x | 101.43x | — |
CL CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE FY ended Dec 31, 2025 | $4.23 | $2.22B | $2.09B | $1.92B | -$85.24M | -$85.55M | -9.61x | 1.15x | — |
CT CTXR Citius Pharmaceuticals, Inc. FY ended Dec 17, 2025 | $0.60 | $16.53M | $38.75M | $90.00K | -$38.67M | -$39.74M | -0.18x | 183.66x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | — | 0/5 | — | — | No saved peers have usable coverage for this method. |
Price / Sales PSActive | Equity Multiple | 62.62x | 5/5 | $3.69M | $0.07 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -9.79x | 5/5 | $766.50M | $14.29 | Peer averages are not economically meaningful for this method. |
